Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study

Authors

• Tareq Al Baghdadi
• Michael Rothe
• Elizabeth Garrett-Mayer
• Funda Meric-Bernstam
• Kathryn Finch Mileham
• Roozbeh Mohajer
• Chukwuemeka Ikpeazu Sr

Recommended Citation

Al Baghdadi T, Rothe M, Garrett-Mayer E, et al. Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study. Journal of Clinical Oncology. 2026/06/01 2026;44(16_suppl):3104-3104. doi:10.1200/JCO.2026.44.16_suppl.3104

Type

Abstract